

Aurealis Pharma to Present at Sachs Associates 16th Annual Biotech in Europe Forum Basel, September 27-28th 2016

Basel Switzerland, Kuopio Finland – September 23rd 2016.

Aurealis Pharma, a privately owned biopharmaceutical company focused on developing novel lactic acid bacteria based multitherapy biologics for patients with chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki, CSO Thomas Wirth, CMO Dirk Weber will attend the 16th Annual Biotech in Europe Forum in Basel Switzerland on September 27-28th 2016, and will present the company and its recent milestones met on Wednesday September 28th 2016 at 11:30 am.

“We are pleased to present our progress and meet investors one-on-one. We have exciting news from our recent regulatory authority meetings and also new pharmacokinetic data of our lead molecule AUP-16” said CEO Juha Yrjänheikki.

Aurealis Pharma is a Basel Switzerland and Kuopio Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper state in chronic inflammation and cancer. Company’s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue to address the unmet medical need in chronic wounds and cancer.

About the 16th Annual Biotech in Europe Forum:

The forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by regular media partners. The organizer expects over 600+ delegates and 100+ presenting companies.

For more information:

Juha Yrjänheikki, CEO

Aurealis Pharma AG

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)

www.aurealispharma.com



AUREALIS PHARMA

Hochbergerstrasse 60C

CH-4057 Basel

Switzerland

www.aurealispharma.com

Microkatu 1

FI-70210 Kuopio

Finland